Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
Authors:
Open Access
- 18 April 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 35 (1) , 2340107
Abstract
Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profiles, treatment outcomes, and drug survival of first-time use of brodalumab for 12 months in adult patients with moderate-to-severe plaque-type psoriasis (with and without PsA) (data cutoff: June 30, 2021). Clinician and patient-reported outcomes of the total cohort (n = 227; PsA, n = 38) indicated a rapid response to brodalumab treatment within the first 3 months, which was maintained up to 12 months. The overall one-year drug survival rate was 76.2%, the mean time to discontinuation was 8.3 months. Reasons for discontinuation were mainly loss/lack of effectiveness, followed by adverse events, contraindication and skin clearance. In sum, brodalumab demonstrated rapid and sustained effectiveness and was well-tolerated over 12 months in German patients with moderate-to-severe psoriasis and PsA in a real-world setting.Keywords
This publication has 36 references indexed in Scilit:
- Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in GreeceJournal of Dermatological Treatment, 2022
- Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyAmerican Journal of Clinical Dermatology, 2019
- PsoriasisNature Reviews Disease Primers, 2016
- Clinical Features and Diagnostic Considerations in Psoriatic ArthritisRheumatic Disease Clinics of North America, 2015
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisNew England Journal of Medicine, 2015
- Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBestArchives of Dermatological Research, 2015
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic ArthritisNew England Journal of Medicine, 2014
- PsoriasisNew England Journal of Medicine, 2009
- The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseasesArchives of Dermatological Research, 2009
- Interim analysis on survival data: its potential bias and how to repair itStatistics in Medicine, 2005